

15 Feb 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by *Scrip's* worldwide team, in this podcast version of Five Must-Know Things.

This episode includes insights from around the biopharma world for the business week ended 12 February 2021.

The major events this time include an analysis of big pharma's US approvals last year, a more convenient antibody regimen for COVID-19, reconfiguring of oncology R&D at one large US firm, one Swiss major's pipeline, and the latest in the *Scrip Asks* series.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and now on [Spotify Podcasts](#) - and also via smart speakers if one of these channels has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020](#)" - Scrip, 5 Feb, 2021.)

(Also see "[Lilly COVID-19 Neutralizing Antibody Combo's Reduced Infusion Time Offers Advantages For Providers](#)" - Scrip, 10 Feb, 2021.)

(Also see "[Lilly Oncology President Anne White On Loxo Success, What's To Come](#)" - Scrip, 9 Feb, 2021.)

(Also see "[Roche Confident But Cautious On Alzheimer's Hopeful](#)" - Scrip, 8 Feb, 2021.)

(Also see "[Scrip Asks...What Does 2021 Hold For Biopharma? Part 4: Technology And Disease](#)" -

Scrip, 9 Feb, 2021.)

[Click here to explore this interactive content online](#) 